CMPX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMPX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Compass Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $1.16.
During the past 12 months, Compass Therapeutics's average Book Value per Share Growth Rate was -19.10% per year. During the past 3 years, the average Book Value per Share Growth Rate was 14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 6 years, the highest 3-Year average Book Value per Share Growth Rate of Compass Therapeutics was 14.20% per year. The lowest was 14.20% per year. And the median was 14.20% per year.
For the Biotechnology subindustry, Compass Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Compass Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Compass Therapeutics's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Compass Therapeutics (NAS:CMPX) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Thank you for viewing the detailed overview of Compass Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard S Lindahl | director | NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191 |
Thomas J. Schuetz | director, officer: Chief Executive Officer | C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063 |
David M Wurzer | director | C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511 |
Vered Bisker-leib | officer: Chief Operating Officer | C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carl L Gordon | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
James P Boylan | director | C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025 |
Ellen Chiniara | director | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Mary Ann Gray | director | 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023 |
Philip Ferneau | director | 10 ALLEN STREET, HANOVER NH 03755 |
Orbimed Capital Gp V Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Genesis Gp Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Miranda Jayne Toledano | director | C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135 |
Susan Kalled | officer: Chief Scientific Officer | COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON MA 02135 |
Brett Kaplan | director | C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016 |
From GuruFocus
By Value_Insider Value_Insider • 11-02-2022
By GuruFocus Research • 11-09-2023
By Marketwired • 11-07-2023
By Marketwired • 08-03-2023
By Stock market mentor Stock market mentor • 01-19-2023
By GuruFocusNews GuruFocusNews • 07-08-2022
By GuruFocusNews GuruFocusNews • 06-28-2022
By PurpleRose PurpleRose • 07-12-2022
By GuruFocusNews GuruFocusNews • 06-18-2022
By sperokesalga sperokesalga • 04-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.